Phase II Study of Cisplatin Plus Epirubicin Salvage Chemo in Refractory Germ Cell Tumors
Status:
Terminated
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
This study proposes to evaluate the combination of cisplatin plus epirubicin in patients with
refractory germ cell tumor not amendable to cure with surgery or standard platinum salvage
chemotherapy. This regimen will be used in eligible patients after progression on ECOG Study
E39897.